HSV/VZV Treatment Recommendations for Adults Indications	
HSV Encephalitis** (Acyclovir 10mg/kg IV Q 8h x 14-21 d) *Foscarnet 80-120mg/kg/d IV in 23 divided doses (for acyclovir-resistant HSV, immunocompromised patients); 3rd line *Foscarnet 90 mg/kg IV Q12h (for acyclovir resistant VZV, immunocompromised patients); 3rd line *Foscarnet 90 mg/kg IV Q12h (for acyclovir resistant VZV, immunocomprompromised patients); 3rd line *Foscarnet 90 mg/kg IV Q12h (for acyclovir resistant VZV, immunocomprompromised patients); 3rd line *Foscarnet 90 mg/kg IV Q12h (for acyclovir resistant VZV, immunocompromised patients); 3rd line *Foscarnet 90 mg/kg IV Q12h (for acyclovir resistant VZV, immunocompromised patients); 3rd line *Foscarnet 90 mg/kg IV Q12h (for acyclovir resistant VZV, immunocompromised patients); 3rd line *Ganciclovir 5 mg/kg IV Q12h (for acyclovir resistant VZV, immunocompromised patients); 3rd line *Foscarnet 90 mg/kg IV Q12h (no clinical triacyclovir spike size of the proposed patients); 3rd line *Ganciclovir 5 mg/kg IV Q12h (for acyclovir resistant VZV, immunocompromised patients); 3rd line *Foscarnet 90 mg/kg IV Q12h (proposed patients); 3rd line *Ganciclovir 5 mg/kg IV Q12h (proposed patients); 3rd line *Foscarnet 90 mg/kg IV Q12h (proposed patients); 3rd line *Ganciclovir 5 mg/kg IV Q12h (proposed patients); 3rd line *Oscarnet Poscarnet Pos	
Carcelovir 10mg/kg IV Clinical trials); 2nd line Foscarnet 80-120mg/kg/d IV in 23 divided doses (for acyclovir-resistant HSV, immunocompromised patients); 3rd line Foscarnet 80-120mg/kg/d IV in 23 divided doses (for acyclovir-resistant HSV, immunocompromised patients); 3rd line CrCL (mL/min) Dose (mg/kg) Foscarnet 80-120mg/kg/d IV in 23 divided doses (for acyclovir-resistant HSV, immunocompromised patients); 3rd line Foscarnet 90 mg/kg IV Q12h (for acyclovir resistant VZV, immunocompromised patients); 3rd line Foscarnet 90 mg/kg IV Q12h (for acyclovir resistant VZV, immunocompromised patients); 3rd line Foscarnet 90 mg/kg IV Q12h (for acyclovir resistant VZV, immunocompromised patients); 3rd line Foscarnet 90 mg/kg IV Q12h until improvement; can switch to oral therapy (see dose below; no clinical triapy (acyclovir 800 mg PO 5 x's/d) to complete 10-14d Tx. For acyclovir-resistant HSV Zoster, immunocom-	
Poscarnet 80-120mg/kg/d IV in 23 divided doses (for acyclovir-resistant HSV, immunocompromised patients); 3rd line Varicella Zoster (severe cases: acyclovir 10mg/kg IV Q8h x 10-14 d, encephalitis; other indications, 7-10 d) ⁴⁻⁷ HSV Zoster (sextensive cutaneous lesion or visceral involvement) in immunocompromised: acyclovir 10 mg/kg IV Q8h until improvement; can switch to oral tx to complete 10-14d witch to oral tx to complete 10-14d witch to oral tx to complete 10-14d resistant HSV Zoster, immunocompromised: acyclovir 800 mg PO 5 x's/d) to complete 10-14d Tx. For acyclovir-resistant HSV Zoster, immunocompromised: acyclovir 800 mg PO 5 x's/d) to complete 10-14d Tx. For acyclovir-resistant HSV Zoster, immunocompromised: acyclovir 800 mg PO 5 x's/d) to complete 10-14d Tx. For acyclovir-resistant HSV Zoster, immunocompromised: acyclovir solution and therapy (acyclovir 800 mg PO 5 x's/d) to complete 10-14d Tx. For acyclovir-resistant HSV Zoster, immunocompromised: acyclovir solution and therapy (acyclovir 800 mg PO 5 x's/d) to complete 10-14d Tx. For acyclovir-resistant HSV Zoster, immunocompromised: acyclovir solution and therapy (acyclovir 800 mg PO 5 x's/d) to complete 10-14d Tx. For acyclovir-resistant HSV Zoster, immunocompromised: acyclovir solution and therapy (acyclovir 800 mg PO 5 x's/d) to complete 10-14d Tx. For acyclovir-resistant HSV Zoster, immunocompromised: acyclovir solution and therapy (acyclovir 800 mg PO 5 x's/d) to complete 10-14d Tx. For acyclovir-resistant HSV Zoster, immunocompromised: acyclovir solution and therapy (acyclovir 800 mg PO 5 x's/d) to complete 10-14d Tx. For acyclovir-resistant HSV Zoster, immunocompromised: acyclovir solution and therapy (acyclovir 800 mg PO 5 x's/d) to complete 10-14d Tx. For acyclovir-resistant HSV Zoster, immunocompromised: acyclovir-resistant HSV Zoste	
23 divided doses (for acyclovir-resistant HSV, immunocompromised patients); 3rd line 23 divided doses (for acyclovir-resistant HSV, immunocompromised patients); 3rd line 25 49 2.5 IV Q24h 10-24 1.25 IV Q24h 10-25 tiw (post-dialysis) or if platelet < 25,000/mi Poscarnet One case report?); 2nd line • Foscarnet • Foscarnet • Foscarnet • Foscarnet • Foscarnet • CrCL (mL/min/kg) Dose (mg/kg) • Phosphorus • Phosphorus • May lower seizure thre limipenem • Do not use if ANC < 5i or if platelet < 25,000/mi • CrCL (mL/min/kg) Dose (mg/kg) • Phosphorus • Phosphorus • Potassium • SCr/BUN • SCr/BUN • SCr/BUN	mia,
resistant HSV, immunocompromised patients); 3rd line Varicella Zoster (severe cases: acyclovir 10mg/kg IV Q8h x 10-14 d, encephalitis; other indications, 7-10 d) ⁴⁻⁷ HSV Zoster ⁶ (extensive cutaneous lesion or visceral involvement) in immunocompromised: acyclovir 10 mg/kg IV Q8h until improvement; can switch to oral tx to complete 10-14d resistant HSV, immunocompromised patients); 3rd line - Ganciclovir 5 mg/kg IV Q12h (for acyclovir resistant VZV, immunocompromised: acyclovir resistant VZV, immunocompromised: acyclovir 10 mg/kg IV Q12h until improvement; can switch to oral tx to complete 10-14d resistant HSV, immunocompromised: acyclovir 10 mg/kg IV Q12h until improvement; can switch to oral tx to complete 10-14d Tx. For acyclovir-resistant HSV Zoster, immunocompromised: acyclovir 10 mg/kg IV Q3 to complete 10-14d Tx. For acyclovir-resistant HSV Zoster, immunocompromised: acyclovir 10 mg/kg IV Q3 to complete 10-14d Tx. For acyclovir-resistant HSV Zoster, immunocompromised: acyclovir 10 mg/kg IV Q15h until improvement; can switch to oral therapy (acyclovir 800 mg PO 5 x's/d) to complete 10-14d Tx. For acyclovir-resistant HSV Zoster, immunocompromised: acyclovir 10 mg/kg IV Q15h until improvement; can switch to oral therapy (acyclovir 800 mg PO 5 x's/d) to complete 10-14d Tx. For acyclovir-resistant HSV Zoster, immunocompromised: acyclovir 10 mg/kg IV Q15h until improvement; can switch to oral therapy (acyclovir 800 mg PO 5 x's/d) to complete 10-14d Tx. For acyclovir-resistant HSV Zoster, immunocompromised: acyclovir 10 mg/kg IV Q15h until Improvement; can switch to oral therapy (acyclovir 800 mg PO 5 x's/d) to complete 10-14d Tx. For acyclovir-resistant HSV Zoster, immunocompromised: acyclovir 10 mg/kg IV Q15h until Improvement; can switch to oral therapy (acyclovir 800 mg PO 5 x's/d) to complete 10-14d Tx. For acyclovir-resistant HSV Zoster, immunocompromised acyclovir 10 mg/kg IV Q15h until Improvement; can switch to oral therapy (acyclovir 800 mg PO 5 x's/d) to complete 10-14d Tx. For acyclovir-resi	
wised patients); 3rd line Varicella Zoster (severe cases: acyclovir 10mg/kg IV Q8h x 10-14 d, encephalitis; other indications, 7-10 d) ⁴⁻⁷ HSV Zoster ⁶ (extensive cutaneous lesion or visceral involvement) in immuno- compromised: acyclovir 10 mg/kg IV Q8h until improvement; can switch to oral tx to complete 10-14d mised patients); 3rd line - Ganciclovir 5 mg/kg IV Q12h one case report ⁷); 2nd line - Foscarnet - CrCL (mL/min/kg) Dose (mg/kg) - CrCL (mL/min/kg) Dose (shold of
Varicella Zoster (severe cases: acyclovir 10mg/kg IV Q8h x 10-14 d, encephalitis; other indications, 7-10 d) ⁴⁻⁷ HSV Zoster ⁶ (extensive cutaneous lesion or visceral involvement) in immuno-compromised: acyclovir 10 mg/kg IV Q8h until improvement; can switch to oral tx to complete 10-14d Varicella Zoster • Ganciclovir 5 mg/kg IV Q12h one case report ⁷); 2nd line • Foscarnet • Foscarnet • CrCL (mL/min/kg) Dose (mg/kg) • Calcium • CrCL (mL/min/kg) Dose (mg/kg) • Calcium • Phosphorus • Magnesium • Potassium • SCr/BUN • SCr/BUN • SCr/BUN • Ganciclovir 5 mg/kg IV Q12h until improvement; can switch to oral therapy (see dose below; no clinical triapy (acyclovir 800 mg PO 5 x's/d) to complete 10-14d Tx. For acyclovir-resistant HSV Zoster, immunocom-	
Varicella Zoster (severe cases: acyclovir (severe cases: acyclovir 5 mg/kg IV Q12h (for acyclovir sesistant VZV, immuno- compromised patients); 3rd line (severe cases: acyclovir 5 mg/kg IV Q12h until improvement; can switch to oral ther- apy (see dose below; no clinical tri- als); 2nd line (see dose below; no clinical tri- als); 2nd line (see dose below; no clinical tri- als); 2nd line (see dose below; no clinical tri- als); 2nd line (see dose below; no clinical tri- als); 2nd line (see dose below; no clinical tri- als); 2nd line (see dose below; no clinical tri- als); 2nd line (see dose below; no clinical tri- als); 2nd line (see dose below; no clinical tri- als); 2nd line (see dose below; no clinical tri- als); 2nd line (see dose below; no clinical tri- als); 2nd line (see dose below; no clinical tri- als); 2nd line (see dose below; no clinical tri- als); 2nd line (see dose below; no clinical tri- als); 2nd line (see dose below; no clinical tri- als); 2n)0/mm ³
(severe cases: acyclovir 10mg/kg IV Q8h x 10-14 d, encephalitis; other indications, 7-10 d) ⁴⁻⁷ HSV Zoster ⁶ (extensive cutaneous lesion or visceral involvement) in immuno-compromised: acyclovir 10 mg/kg IV Q8h until improvement; can switch to oral tx to complete 10-14d Foscarnet - Foscarnet - CrCL (mL/min/kg) Dose (mg/kg) - Calcium - CorCL (mL/min/kg) Dose (mg/kg) - Calcium - Phosphorus - Phosphorus - Nagnesium - Potassium - Potassium - Potassium - Potassium - Potassium - Potassium - O.4-0.5 - 35 IV Q24h - O.4-0.5 - 35 IV Q24h - O.4-0.5 - 35 IV Q24h - O.4-0.5 - O.4 - Avoid use - Foscarnet - CrCL (mL/min/kg) Dose (mg/kg) - Phosphorus - Nagnesium - Potassium - Potassium - Potassium - Potassium - O.4-0.5 - O.4 - O.4 - O.5 - O.5 - O.6 - O.7 -	n^3
10mg/kg IV Q8h x 10-14 d, encephalitis; other indications, 7-10 d) ⁴⁻⁷ HSV Zoster ⁶ (extensive cutaneous lesion or visceral involvement) in immunocompromised: acyclovir 10 mg/kg IV Q8h until improvement; can switch to oral tx to complete 10-14d where the following interest of the complete 10-14d improvement; can switch to oral therapy (acyclovir 800 mg PO 5 x's/d) to complete 10-14d Tx. For acyclovir resistant HSV Zoster, immunocom- erc L (mL/min/kg) Dose (mg/kg) >1.4 40 IV Q8h • Phosphorus • Potassium • Potassium • Potassium • SCr/BUN • CrCL (mL/min/kg) Dose (mg/kg) • Au IV Q8h • Au IV Q8h • O.4-0.5 35 IV Q24h • O	
encephalitis; other indications, 7-10 d) ⁴⁻⁷ acyclovir resistant VZV, immuno- compromised patients); 3rd line HSV Zoster ⁶ (extensive cutaneous lesion or visceral involvement) in immuno- compromised: acyclovir 10 mg/kg IV Q8h until improvement; can switch to oral tx to complete 10-14d which is a cyclovir resistant VZV, immuno- compromised patients); 3rd line • Ganciclovir 5 mg/kg IV Q12h until improvement; can switch to oral therapy (see dose below; no clinical trials); 2nd line • Foscarnet 90 mg/kg IV Q12h until improvement; can switch to oral therapy (acyclovir 800 mg PO 5 x's/d) to complete 10-14d Tx. For acyclovir- resistant HSV Zoster, immunocom- • Phosphorus • Magnesium • Potassium • SCr/BUN • Condition of the condition of the condition of the condition of the complete 10-14d Tx. For acyclovir- resistant HSV Zoster, immunocom-	
7-10 d) ⁴⁻⁷ Compromised patients); 3rd line Consetute of the patients of the pa	
HSV Zoster ⁶ (extensive cutaneous lesion or visceral involvement) in immunocompromised: acyclovir 10 mg/kg IV Q8h until improvement; can switch to oral tx to complete 10-14d HSV Zoster ⁶ • Ganciclovir 5 mg/kg IV Q12h until improvement; can switch to oral therapy (see dose below; no clinical trials); 2nd line • Foscarnet 90 mg/kg IV Q12h until improvement; can switch to oral tx to complete 10-14d • Potassium • SCr/BUN • Potassium • SCr/BUN • Potassium • SCr/BUN	
+ Ganciclovir 5 mg/kg IV Q12h until improvement; can switch to oral trialswitch to oral tx to complete 10-14d - Ganciclovir 5 mg/kg IV Q12h until improvement; can switch to oral therapy (see dose below; no clinical trials); 2nd line - Foscarnet 90 mg/kg IV Q12h until improvement; can switch to oral tx to complete 10-14d - Ganciclovir 5 mg/kg IV Q12h until improvement; can switch to oral therapy (see dose below; no clinical trials); 2nd line - Foscarnet 90 mg/kg IV Q12h until improvement; can switch to oral therapy (acyclovir 800 mg PO 5 x's/d) to complete 10-14d Tx. For acyclovir-resistant HSV Zoster, immunocom-	
(extensive cutaneous lesion or visceral involvement) in immuno- compromised: acyclovir 10 mg/kg IV Q8h until improvement; can switch to oral therapy (acyclovir 800 mg PO 5 x's/d) to complete 10-14d Tx. For acyclovir- resistant HSV Zoster, immunocom-	
ceral involvement) in immuno- compromised: acyclovir 10 mg/kg IV Q8h until improvement; can switch to oral tx to complete 10-14d with the oral tx to complete 10-14d switch to oral tx to complete 10-14d apy (see dose below; no clinical trials); 2nd line • Foscarnet 90 mg/kg IV Q12h until improvement; can switch to oral therapy (acyclovir 800 mg PO 5 x's/d) to complete 10-14d Tx. For acyclovir- resistant HSV Zoster, immunocom-	
compromised: acyclovir 10 mg/kg IV Q8h until improvement; can switch to oral tx to complete 10-14d switch to oral tx to complete 10-14d improvement; can switch to oral therapy (acyclovir 800 mg PO 5 x's/d) to complete 10-14d Tx. For acyclovir-resistant HSV Zoster, immunocom-	
IV Q8h until improvement; can switch to oral tx to complete 10-14d improvement; can switch to oral therapy (acyclovir 800 mg PO 5 x's/d) to complete 10-14d Tx. For acyclovir-resistant HSV Zoster, immunocom-	
switch to oral tx to complete 10-14d improvement; can switch to oral therapy (acyclovir 800 mg PO 5 x's/d) to complete 10-14d Tx. For acyclovir-resistant HSV Zoster, immunocom-	
apy (acyclovir 800 mg PO 5 x's/d) to complete 10-14d Tx. For acyclovir-resistant HSV Zoster, immunocom-	
complete 10-14d Tx. For acyclovir- resistant HSV Zoster, immunocom-	
resistant HSV Zoster, immunocom-	
promised patients. 3rd line	
Severe HSV infection • Ganciclovir 5 mg/kg IV Q12h x 14-	
(disseminated, pneumonitis, CNS, 21 days (no clinical trials); 2nd line	
liver) in immunocompromised8: • Foscarnet 40 mg/kg IV Q8h x	
acyclovir 10mg/kg IV Q8h x 14-21	
days. For mucocutaneous infection, HSV,immunocompromised patients);	
genital infection, or for immuno- 3rd line	
competent, use 5 mg/kg IV Q 8h.8	